×

Traders see money in this drug stock

Investors are flocking to health care stocks.

The health-care sector has already seen sky-high returns this past year, up more than 25 percent with companies like Regeneron Pharmaceuticals, Cigna and Edwards Lifesciences leading the rally, up a respective 87, 82 and 71 percent in the same period. But it's one of the sector's underperformers that sparked a flurry of bullish activity in the options market this week: Pfizer.

On Tuesday, when options call volume ran more than two times its daily average, and calls traded eight times more than puts, one options trader bet nearly $1 million that the stock could rally to multiyear highs in the next four months. Specifically, that trader purchased 10,000 of the October 35-strike calls for 76 cents each. Since buying a call option allows a trader to purchase a stock at a set price at a given time, this trade is profitable if Pfizer shares rise above $35.76 or 4 percent from current levels by October expiration. That's the highest level for the stock in more than a decade.

"This trade was unusual on a relatively light volume day, as it represents about a million shares of stock," options expert and CNBC Contributor Mike Khouw said Tuesday on CNBC's "Fast Money."

Khouw added that the trade could have been a result of an upgrade from Jefferies, who reaffirmed their buy rating Tuesday and added a $45 price target on the stock.

Of the 20 Wall Street analysts that cover Pfizer, the average rating is overweight with a price target of $37.74.

Latest Video

Tutorials

Host Bio

  • Melissa Lee

    Melissa Lee is the host of CNBC's “Fast Money” and “Options Action.”

Options Action Traders

From Our Sponsor

Options Action Newsletter:

Sign up to receive exclusive Options Action content. Each month you'll receive an exclusive message from host Melissa Lee and insight directly from one of the members of our Options Action panel. Keep your pulse on the market with the Options Action newsletter.

Please enter a valid email address
To learn more about how we use your information, please read our Privacy Policy.